Sustainability Positioning for Waterless Skincare: Carbon Footprint & Claim Support

Overview #

Waterless formulation is not a trend we’re chasing. It’s a structural shift in how we think about product architecture — and the sustainability angle is only half the story. The more interesting half is ingredient performance. When you remove water as the primary carrier, every active you choose behaves differently: solubility changes, delivery kinetics change, and the stability envelope you’re working within gets tighter. Most brands come to us with a sustainability brief and leave with a completely different understanding of what waterless actually demands at the formulation level.

Why Waterless Changes the Ingredient Selection Game #

The obvious sustainability wins are real. Removing water from a formula typically reduces shipping weight by 60–80% compared to an equivalent aqueous product, and eliminates the need for broad-spectrum aqueous preservative systems. That’s a meaningful carbon reduction story, and it’s one we can support with actual logistics data when brands need claim documentation. But the ingredient selection consequences are less obvious.

In an anhydrous or low-water system (we define “low-water” as anything below 5% w/w free water), you lose the solvent matrix that most actives were originally designed for. Vitamin C as L-ascorbic acid? Essentially unusable — it oxidizes within weeks in the absence of a buffered aqueous phase. Hyaluronic acid? It needs water to hydrate and form its characteristic film. This is not a dealbreaker; it just means you’re selecting from a fundamentally different ingredient palette.

The table below compares established waterless actives against next-generation alternatives we’re actively working with across current client projects.

A few things worth noting about this table. The cost indices are based on our current supplier pricing at 100kg order quantities — they shift at scale, and some of the newer actives drop significantly above 500kg. Also, “stability” here means the ingredient itself, not necessarily the finished formula. A stable ingredient in an unstable emulsion architecture is still a failed product.

For brands building a sustainability narrative, the ingredient sourcing story matters as much as the waterless claim itself. Squalane from sugarcane fermentation (not shark liver) is now the default we specify — it’s price-competitive and the origin documentation is clean for EU and US market claims. Bakuchiol from Psoralea corylifolia seed extract has a more complicated supply chain story; we’ve had two supplier qualification failures in the past 18 months because of inconsistent babchi oil sourcing. We now require ISO 22000 certification and batch-level COA with HPLC purity data before we approve a new bakuchiol supplier.

For deeper context on how we handle retinoid alternatives in oil-based systems, see our Retinoid Technology formulation guide.

Actives That Actually Work — and the Ones That Sound Better Than They Are #

Let’s talk about ascorbyl tetraisopalmitate (ATIP) first, because it comes up in almost every waterless vitamin C brief. It’s oil-soluble, it’s stable in anhydrous systems, and the marketing story writes itself. At 2.0–3.0%, we see reasonable antioxidant activity and some brightening effect in consumer perception studies. The clinical evidence for melanin inhibition is thinner than most suppliers will admit — we’re still not fully convinced the in-vitro tyrosinase inhibition data translates cleanly to in-vivo brightening at the concentrations that are cost-viable. That said, it’s the best vitamin C option we have for waterless formats, and we use it regularly.

Bakuchiol is the one we get the most questions about. The head-to-head data against retinol is actually pretty clear at this point. One double-blind RCT (n=44, 12 weeks) showed comparable reductions in fine lines and pigmentation between 0.5% bakuchiol twice daily and 0.5% retinol once daily, with significantly lower irritation scores in the bakuchiol arm. What that study doesn’t capture — and what we’ve learned from our own batches — is the stability variability between suppliers. We’ve run identical formulas with bakuchiol from three different suppliers and gotten meaningfully different 3-month stability outcomes. The active content at week 12 ranged from 87% to 96% of label claim depending on source. That spread matters for efficacy claims.

Encapsulated retinol in lipid matrix is genuinely useful for waterless formats. The encapsulation protects the retinol from oxidation during the anhydrous processing phase, and it allows controlled release on skin. The catch is cost. Encapsulation adds roughly 3× the raw material cost compared to unencapsulated retinol at equivalent active loading. At MOQ 1000 units, that’s often a $0.60–$1.20 per unit COGS impact that indie brands haven’t budgeted for. We’ve had more than a few projects stall at this point. Honestly, most brands underestimate this.

For brands interested in the broader encapsulation technology picture, our Encapsulation Technology guide covers the full range of systems we work with.

One active we’re increasingly bullish on: oil-dispersible polyglutamic acid (PGA). Traditional PGA is water-soluble and useless in anhydrous systems. The modified oil-dispersible grades now available from two Japanese suppliers can be incorporated at 0.5–1.0% in lipid-continuous systems and deliver measurable surface hydration improvement even without free water in the formula. The mechanism is different from aqueous PGA — it’s more of a surface occlusion and hygroscopic draw effect — but the consumer perception data is strong. We haven’t fully solved the long-term stability picture at elevated temperatures. Our current approach works at 25°C storage but we’re seeing some viscosity drift at 40°C in certain base formulations. It’s not a perfect solution.

The Carbon Claim Problem — What You Can Actually Say #

This is usually where projects go sideways. A brand comes in wanting to claim “70% lower carbon footprint” on pack, and we have to have a difficult conversation about what’s actually defensible.

The waterless format does reduce transport emissions. A concentrated solid serum or anhydrous balm at 15g delivers equivalent active dose to a 50ml aqueous serum — that’s a real weight and volume reduction. If you’re shipping from our facility in China to a distribution center in the EU, the per-unit carbon reduction from logistics alone can be documented at 40–65% depending on the product format and shipping mode. We work with third-party LCA (Life Cycle Assessment) providers to generate the supporting data when clients need it for EU Green Claims compliance.

The problem is the full lifecycle picture. Manufacturing energy, raw material extraction, packaging end-of-life — these factors can partially offset the logistics gains. A waterless formula in a non-recyclable multi-layer laminate tube is not a clean sustainability story, regardless of what the formula contains. We almost always push back on this brief when the packaging spec doesn’t match the sustainability positioning.

Under the EU Cosmetics Regulation 1223/2009 and the incoming EU Green Claims Directive, environmental claims on cosmetic products must be substantiated with verifiable evidence. “Waterless” as a claim is currently unregulated in terms of definition — there’s no official threshold — but “lower carbon footprint” or “eco-friendly” claims are increasingly scrutinized. The FDA Cosmetics Guidelines take a lighter-touch approach to environmental claims, but FTC Green Guides still apply in the US market and require that comparative claims be specific and substantiated.

For brands targeting the Chinese market, the NMPA Cosmetic Regulation framework doesn’t yet have specific guidance on waterless or sustainability claims, but the general prohibition on false or misleading claims applies. We’ve seen NMPA reviewers flag “waterless” claims during registration when the formula contained more than 3% water from ingredient carry-in. Worth knowing before you finalize your formula spec.

Where Scale-Up Actually Fails #

Lab scale and production scale are different worlds. This is the section most ingredient guides skip.

At 500g lab scale, anhydrous formulas are generally forgiving. You’re mixing in a jacketed beaker, temperature control is precise, and you can hand-mix to homogeneity. At 200kg production scale, the dynamics change. We had one project — a waterless vitamin C balm with ATIP at 2.5% and bakuchiol at 1.0% — that was perfect through three lab iterations. First production batch at 150kg showed visible phase separation at week 6 of stability testing. The root cause was shear rate differential during the production mixing cycle causing partial crystallization of the ATIP at the processing temperature we were running. We dropped the mixing temperature by 8°C and extended the homogenization cycle by 12 minutes. Second batch passed. But that failure cost the client four weeks and a partial batch write-off.

The other failure mode we see regularly in waterless systems is microbial ingress during filling. Anhydrous formulas don’t support microbial growth, but they can carry contamination from the filling environment into the package. If the consumer introduces water — even from wet hands — you can get localized microbial growth at the product surface. We now require all waterless products to be filled in ISO Class 7 cleanroom conditions minimum, and we challenge-test the finished product under simulated use conditions (repeated water introduction) as part of our standard stability protocol. This is not standard practice across the industry. It should be.

Fragrance is another one. We’ve seen emulsion-adjacent anhydrous systems destabilize when fragrance load exceeds 0.8% in certain base architectures. The fragrance solvents — particularly those containing high proportions of benzyl alcohol or linalool — can act as co-solvents and disrupt the lipid matrix structure. Short answer: keep fragrance below 0.5% in complex anhydrous actives systems until you’ve run the compatibility data.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? These are the first two questions we ask when a waterless brief comes in, because the answers determine almost everything about ingredient selection.

If you’re targeting EU clean beauty retail, the ingredient palette narrows quickly. Certain silicones, some synthetic emollients, and several preservative boosters that work well in anhydrous systems are on retailer restricted lists — not regulatory banned lists, but effectively off the table for that channel. We maintain an updated retailer restriction matrix for Sephora EU, Douglas, and Boots that we share with brand partners at brief intake.

If you’re targeting US mass or drug channel, the cost pressure is different and the clean beauty restrictions are less acute, but the stability requirements for ambient warehouse storage (which can hit 35°C in summer) are more demanding than you’d expect.

For a typical waterless serum-balm targeting EU premium retail, our starting architecture is a squalane-jojoba ester base at 40–50% combined, with ceramide NP at 0.5%, ATIP at 2.0%, bakuchiol at 1.0%, and tocopherol at 0.5% as antioxidant protection. That’s a formula that passes our internal 12-week accelerated stability at 40°C/75% RH and supports a clean ingredient story. From there, we layer in the brand’s hero active — peptide complex, botanical extract, whatever the positioning requires. MOQ for this type of formula is typically 500kg finished product, which translates to roughly 33,000 units at 15g fill weight.

Frequently Asked Questions #

Q: Can we claim “100% waterless” if we’re using plant extracts that contain some water?

Technically, most botanical extracts carry residual water — sometimes 5–10% of the extract weight. At typical use levels of 0.5–2.0%, the water contribution to the finished formula is usually below 0.5% w/w total. We’d recommend claiming “waterless formula” rather than “100% waterless” and being prepared to show the water activity (Aw) data, which for a well-formulated anhydrous system should be below 0.6. That number is what actually matters for preservation and stability, not the theoretical zero-water claim.

Q: We want to use live probiotics in a waterless format for the microbiome story — is that viable?

Honestly, we’ve stopped taking most live probiotic briefs unless the brand is prepared for encapsulation costs upfront. Viable organism counts in anhydrous systems drop fast — we’ve seen 2-log reductions within 8 weeks at ambient storage without specialized encapsulation. If you want a microbiome positioning, postbiotics or lysate-based actives are far more stable in waterless formats and the clinical evidence base is actually stronger than most people realize. The live organism story sounds better in marketing decks than it performs in stability chambers.

Q: What’s the minimum order quantity for a custom waterless formula?

Our standard MOQ for a custom anhydrous formula is 200kg bulk, which typically yields 10,000–15,000 units depending on fill weight. For pilot batches during development, we run 20kg trial batches at a fixed development fee. The pilot batch is critical for waterless formats — don’t skip it to save cost, because scale-up surprises are more common in anhydrous systems than in standard aqueous emulsions.

Q: How do we substantiate a “lower carbon footprint” claim for EU retail?

You need a comparative LCA against a reference product — typically the aqueous equivalent at equivalent active dose. We partner with a third-party LCA provider and can coordinate the study as part of the development project. Budget 8–12 weeks and approximately €3,000–€5,000 for a basic comparative LCA with documentation suitable for EU Green Claims compliance. Without that documentation, retailers like Sephora EU are increasingly declining to accept environmental claims on pack. The SCCS Scientific Opinion framework and EU Green Claims Directive are the relevant reference points here.

Q: Is bakuchiol actually equivalent to retinol, or is that just marketing?

The clinical data is more credible than the skeptics suggest. The RCT we reference most often (n=44, 12 weeks, twice-daily 0.5% bakuchiol vs. once-daily 0.5% retinol) showed statistically comparable outcomes on fine line depth and skin tone evenness, with bakuchiol showing lower rates of erythema and desquamation. But “equivalent” is doing a lot of work in that sentence. Retinol has a 30-year evidence base; bakuchiol has maybe 6–8 years of serious clinical data. For a brand that needs a retinoid-free positioning — pregnancy-safe claims, sensitive skin, EU retail restrictions on retinol in certain product types — bakuchiol at 1.0–2.0% is a legitimate choice. For a brand that just wants maximum anti-aging efficacy and has no positioning constraints, we’d still lean toward encapsulated retinol. See the ICH Stability Guidelines for the stability testing framework we apply to both.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.